Analysts Review on Trending Stock: Pharmacyte Biotech Inc (PMCB), Growlife Inc (PHOT), Earth Science Tech Inc (ETST)

Analysts Review on Trending Stock: Pharmacyte Biotech Inc (PMCB), Growlife Inc (PHOT), Earth Science Tech Inc (ETST)

Analysts Review on Trending Stock: Pharmacyte Biotech Inc (PMCB), Growlife Inc (PHOT), Earth Science Tech Inc (ETST)

Pharmacyte Biotech Inc (OTCMKTS:PMCB) showing dropped of -2.43% and closed at $0.0965, after gaining total volume of 1.39 million shares. Its earnings per share (EPS) is -$0.01 and its beta value stands at 2.44 points and has total market capitalization of $85.24 million and a total of 875.31 million outstanding shares.

PharmaCyte Biotech, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology, known as Cell-in-a-Box. Its Cell-in-a-Box technology would be used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, and diabetes. The company is developing therapies for pancreatic and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of the cancer. It is also developing a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes; and examining the benefits of the Cell-in-a-Box technology to develop therapies for cancer based upon the constituents of the Cannabis plant. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was founded in 1996 and is based in Silver Spring, Maryland.

Growlife Inc (OTCMKTS:PHOT) increased 1.98% closed at $0.0103 and traded with total volume of 6.55 million shares, while the average trading remained 19.10 million shares. During last trade its minimum price was $0.00 and it gained the highest price of $0.01. Its market capitalization was $16.01 million.

Growlife Inc (PHOT) on February 15, 2017 announced the expansion of its Board of Directors and management team.

As GrowLife seeks to capitalize on the increasing demand for indoor cultivation by commercial growers as well as consumers, along with the recent announcement of GrowLife’s Retail License Program, it has added two experienced executives to its board of directors: Ms. Katherine McLain, corporate counsel for Stripe and the return to the Board of Mr. Mark Scott, GrowLife CFO.

“Our new board members strengthen the GrowLife bench and deepen the resources across finance, legal and operations,” stated Mr. Marco Hegyi, GrowLife Chairman and CEO. “Katherine brings Silicon Valley legal knowledge and banking expertise from Stripe and Silicon Valley Bank, and Mark rejoins the board and adds a second executive board member perspective.” Their brief biographies are listed below.

In addition, Mr. Darren Erasmus, a well-respected cultivation industry leader from House & Garden Nutrients, has joined the Company as its National Sales Manager.

“Darren’s wealth of experience and unparalleled network is a powerful and critical addition to GrowLife,” continued Mr. Hegyi. “He will help Joe Barnes, Senior Vice-president of Business Development, build our Sales team, GrowLife’s focus on nationwide revenue expansion, and recruit stores into the GrowLife Retail License Program.”

The GrowLife Retail License Program was announced last month. Its first licensee is Fairmount Hardware, an Ace Hardware franchise, located at 2011 Fairmount Ave, Philadelphia, PA. The store is completing its training, inventory stocking and customer engagement steps to go live next month. More details on obtaining a GrowLife licenses in locations in selected markets across the country can be found at

Earth Science Tech Inc (OTCMKTS:ETST) reported the surge of 5.56% and closed at $1.90, with the total traded volume of 16,211.00 shares. During last trade its minimum price was $1.85 and it gained its highest price of $2.05 and has a total of 77.73 million outstanding shares.

On February 28, 2017 Earth Science Tech, Inc. (ETST), an innovative biotech company focused on cannabis (industrial hemp) and cannabinoid research and development, nutraceuticals, pharmaceuticals, and medical devices, and its subsidiary Cannabis Therapeutics Inc. are proud to announce that Dr. Moutih Rafei, PhD, has joined the company’s Advisory Board and that three out of the five distinguished scientists and doctors who were recently nominated to the companies’ Advisory Board will meet on Tuesday, February 28th at Le Centre Québecois d’Innovation en Biotechnologie (CQIB) in Laval, Québec, (

There will be a press availability and photo op.

Dr. Chandra Panchal, Dr. Domenico Fuoco, and Dr. Moutih Rafei will meet at the biotech business incubator to review and discuss ETST’s ongoing R&D projects and chart the direction of the company’s research and development initiative for near future. Missing from the gathering will be Dr. Laurent Azoulay and Dr. Calvin Higgins, M.D. who cannot leave their current work at this time. Also in attendance will be Dr. Michel Aubé, PhD, CEO and Chief Scientific Officer of ETST and Cannabis Therapeutics, Inc.

At this meeting, the company will also formally launch its R&D partnership with Smart Medicine, Inc. who will provide laboratory and technical services to ETST in their facility at CQIB.

ESTS R&D is focused on the development and manufacturing of nutraceutical products, generic drugs, and cannabiniod-based medicine. The company’s goal is to market its new generic drug formulations and to find new applications for those generic drugs. The development of new improved formulations of existing generic drugs will aid in the discovery of treatment for diseases that are not currently treated with those generic drugs.


Investing is speculative. When investing your capital is at risk. This site is not intended for use in jurisdictions in which the trading or investments described are prohibited and should only be used by such persons and in such ways as are legally permitted. Your investment may not qualify for investor protection in your country or state of residence, so please conduct your own due diligence. This website is free for you to use but we may receive commission from the companies we feature on this site. Click here for more information.